Post Menopausal Osteoporosis - Pipeline Review, H1 2018

Publication ID:
GMD0418041

Publication Date:
April 24, 2018

Pages:
87

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
- Single User License (PDF), $2,000.00
- Site License (PDF), $4,000.00
- Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
**Description:**

Post Menopausal Osteoporosis - Pipeline Review, H1 2018

**Summary**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2018, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

**Report Highlights**

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 5, 2, 3 and 6 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

**Scope**

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal
Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ipsen SA
Lupin Ltd
Luye Pharma Group Ltd
NIBEC
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Uni-Bio Science Group Ltd
Post Menopausal Osteoporosis - Drug Profiles
(cholecalciferol + risedronate sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcitonin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

**teriparatide - Drug Profile**

**Product Description**

**Mechanism Of Action**

**R&D Progress**

**teriparatide biosimilar - Drug Profile**

**Product Description**

**Mechanism Of Action**

**R&D Progress**

Post Menopausal Osteoporosis - Dormant Projects

Post Menopausal Osteoporosis - Discontinued Products

Post Menopausal Osteoporosis - Product Development Milestones

**Featured News & Press Releases**

**Mar 22, 2018:** Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC

**Mar 12, 2018:** Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS (abaloparatide) Injection

**Jan 07, 2018:** European Medicines Agency Accepts Filing For EVENITY

**Dec 15, 2017:** Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture

**Nov 06, 2017:** UCB to Present Data On Investigational Drug Romosozumab At 2017 ACR/ARHP Annual Meeting

**Oct 13, 2017:** Radius Health to Present First Health Economics Data on TYMLOS (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017

**Sep 11, 2017:** EVENITY (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

**Sep 08, 2017:** Radius Health Presents Positive Data for TYMLOS (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting

**Sep 08, 2017:** Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

**Sep 08, 2017:** UCB highlights latest EVENITY research at the American Society for Bone and Mineral Research Annual Meeting

**Sep 01, 2017:** Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection

**Jul 21, 2017:** Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

**Jul 16, 2017:** Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The
US
Jun 14, 2017: New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis
May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H1 2018
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2018
Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2018
Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018
Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H1 2018
Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H1 2018
Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2018
Post Menopausal Osteoporosis - Pipeline by NIBEC, H1 2018
Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, H1 2018
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
Post Menopausal Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2018
Post Menopausal Osteoporosis - Dormant Projects, H1 2018
Post Menopausal Osteoporosis - Discontinued Products, H1 2018

List of Figures
List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2018
Number of Products by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:
Amgen Inc
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ipsen SA
Lupin Ltd
Luye Pharma Group Ltd
NIBEC
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Uni-Bio Science Group Ltd

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional
office.

- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Drug Pipeline

No. 1101, Golden Square, 3rd Floor, 24th Main, J P Nagar, 1st Phase, Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us
RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/post-menopausal-osteoporosis-pipeline-review-h1-2018

Links
[1] https://www.drugpipeline.net/region/global